Navigation Links
Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences
Date:12/1/2011

al models demonstrated that resistance to aromatase inhibitors occurs through up-regulation of growth factor signaling pathways and down-regulation of estrogen receptor-alpha (ERa). Entinostat effectively down-regulates growth factor signaling in breast cancer cells where these pathways are active. Entinostat also up-regulates the expression of ER in breast cancer cells which have negligible or undetectable levels of ER. The ability to target multiple mechanisms of resistance establishes entinostat as a promising candidate for preventing and overcoming aromatase inhibitor resistance through epigenetic modulation. In pre-clinical testing entinostat induced tumor regression when combined with an aromatase inhibitor after the development of hormone resistance.

Additional phase 2 studies with entinostat have demonstrated promising results in combination with the EGFR-TKI erlotinib (ENCORE 401) and DNA methyltransfer inhibitor azacitidine in non-small cell lung cancer).  Results from the ENCORE clinical program have provided the basis for moving entinostat in pivotal, phase 3 testing across a platform of breast and lung cancer indications.

About Syndax
Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, late-stage, oncology-focused pharmaceutical company. The company is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Syndax has worldwide rights to develop and commercialize entinostat which has shown promise in randomized clinical trials in solid tumors. Syndax is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures. Formed in 2005, Syndax's intelle
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
2. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
4. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
5. Biogen-Idecs BG-12 Shines At the Top of the Charts in the Treatment of Relapsing-Remitting Multiple Sclerosis
6. Neurology Devices Market to 2017 - High Potential for Usage of Neurostimulation Devices in Multiple Neurological Disorders to Drive Market Growth
7. Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
8. DxTerity and Caliper Life Sciences Partner to Deliver NEAT® Multiplex Assays on Calipers LabChip® Dx Platform
9. Nutra Pharma Receives Patent for Their Multiple Sclerosis Drug
10. S1P1 Agonists are Currently Indicated For Treatment of Multiple Sclerosis
11. Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014  Alere Inc. (NYSE: ALR ... following statement today in support of President Barack ... "As the global leader in rapid diagnostics for infectious ... strategy to address the serious threat of antibiotic resistance. ... Administration on initiatives to promote the development of rapid ...
(Date:9/19/2014)... LONDON , September 19, 2014 ... hat Pharma IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, ... abdeckt. Die interaktive PDF, verfügbar unter pharmaserialisation.com ... an dem sie jeweils in Kraft treten. ... der Serialisierung nicht länger um das "ob", sondern ...
(Date:9/19/2014)... Reductions in kidney failure obtained ... people with diabetes type 2 "Intensive treatment ... the kidneys." Australian researchers have discovered that ... leads to persistent reductions in kidney failure many years ... study has found that, five and a half years ...
Breaking Medicine Technology:Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John ... Watch the Video "Congratulations ... campaign trail to earn the trust and votes of the American ... the state of our economy and jobs. "There ...
... HOPKINTON, Mass., Nov. 3, 2010 ... ), a leading provider of tools and services ... announced a collaboration with Sony DADC Austria AG ... for Caliper,s next generation microfluidics products. The agreement ...
Cached Medicine Technology:PhRMA CEO John Castellani Responds to Mid-Term Election, Stresses Importance of Innovation to Help Grow Economy 2PhRMA CEO John Castellani Responds to Mid-Term Election, Stresses Importance of Innovation to Help Grow Economy 3Caliper Life Sciences and Sony DADC Collaborate to Develop Plastic Microfluidic Solutions 2
(Date:9/21/2014)... “Cluster headaches are sometimes called ‘Suicide Headaches’ because ... said Steve Young of Ew Publishing; “I’ve had cluster ... is more intense.” , “It should be a relief ... that medical research is pointing to some relief and ... Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous biochemical found in ...
(Date:9/21/2014)... Mills, Md. (PRWEB) September 21, 2014 Faculty ... school with a coed preschool in Owings Mills, Md., kicked ... wellness with Garmin Vivofit bands. GFS is the first independent ... steps taken, calories burned and even sleep patterns— as part ... a Baltimore area running and walking specialty chain. The Vivofit ...
(Date:9/21/2014)... Top10BestSEOHosting.com, a leading review website, has recently announced ... most recommended hosting suppliers for the webmasters worldwide ... , “Don’t waste your time on searching ... hosting companies to you,” the IT manager of ... are the most recommended suppliers for everyone. A ...
(Date:9/20/2014)... Las Vegas, NV (PRWEB) September 21, 2014 ... created by Dr. Kenneth Pullman that is helping thousands ... reverse their diabetes symptoms without shots, pills, or prescriptions ... investigative review. , “There are currently tens of ... with both Type 1 and Type 2 diabetes, and ...
(Date:9/20/2014)... September 20, 2014 David Cooke presented ... The first poster looked at the clinical benefits of ... for calculating diastolic function. In conjunction with colleagues at ... disease and normal LVEF by echo (>50%). Each patient ... and standard SPECT. Emory Toolbox 4.0 was ...
Breaking Medicine News(10 mins):Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Garrison Forest School Leader in Independent School Wellness Programs 2Health News:Leading Review Website Top10BestSEOHosting.com Unveils The Best Hosting Suppliers In September 2Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 3
... Medco Health,Solutions, Inc. (NYSE: MHS ) is ... On Monday, March 17, 2008, Timothy C. Wentworth, ... Medco,s specialty pharmacy,subsidiary, is scheduled to address the 28th ... the Boston Marriott Copley,Place will begin at 1:45 p.m. ...
... may not be getting them, study says , , MONDAY, March ... dictate treatment choices for kidney cancer more than clinical factors ... new study finds. , This means many patients who ... partial nephrectomy where only part of the kidney is removed, ...
... A novel drug that fully eliminated brain tumors from ... darker sidecausing permanent bone damage in younger mice. The ... finding raises concerns about using similar drugs to treat ... thorough understanding of possible risks. , Tom Curran, Ph.D., ...
... for osteoporosis or who do not respond to treatment ... affects their quality of life. There is an ... address their issues when new therapies are assessed and ... Professor Cyrus Cooper from the MRC Epidemiology Resource Centre, ...
... Inc. (Nasdaq: PBIO ) today announced that ... Avenue in South Easton, Massachusetts. This,move was necessary ... and development company to a fully commercial,operation. Richard ... now have approximately 5,500 square feet, with sufficient,office, ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... that it is scheduled to,present from 8:30 a.m. to ... Brothers Eleventh Annual Global Healthcare Conference in Miami,Florida., ... a live audio web cast,which may be accessed by ...
Cached Medicine News:Health News:Medco to Present at Cowen and Company and Lehman Brothers Health Care Conferences 2Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 2Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 3Health News:Potential brain cancer drug for children may damage bones 2Health News:Potential brain cancer drug for children may damage bones 3Health News:Make or break time for osteoporosis treatment 2Health News:Pressure BioSciences, Inc. Announces Move to New Corporate Offices 2Health News:Gentiva(R) Health Services to Present March 18th at Lehman Brothers Eleventh Annual Global Healthcare Conference in Miami 2Health News:Gentiva(R) Health Services to Present March 18th at Lehman Brothers Eleventh Annual Global Healthcare Conference in Miami 3
The Electric H-Base Table is for heavier instruments, or for those who prefer electric elevation. The electric table easily accepts a slit lamp, a single tabletop, or a double tabletop, just as the M...
The Manual Table Base is elevated with an easy to reach elevating wheel for smooth operation. The table base will accept a slit lamp, a single table top, or a double tabletop for more than one instru...
A new, innovative design compliments the proven, 30-year mechanical operating system....
The Encore Stand combines the proven mechanical structure and durability of the popular Deluxe Stand, with a modern, sophisticated appearance....
Medicine Products: